{"success":true,"data":{"pressRelease":{"id":"136174","rtpr_id":"nNFC8YcSLt-20260904","ticker":"CTSO","exchange":"NASDAQ","all_tickers":["CTSO"],"title":"CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference","author":"Newsfile Corp","published_at":"2026-09-04T13:09:35.616Z","article_body":"Princeton, New Jersey--(Newsfile Corp. - September 4, 2026) - CytoSorbents\nCorporation (https://api.newsfilecorp.com/redirect/87VN2t5nvJ) (NASDAQ: CTSO),\na leader in the treatment of life-threatening conditions in the intensive care\nunit and cardiac surgery using blood purification, is pleased to announce its\nparticipation at the upcoming Moody Capital Solutions 2026 Disruptive Growth &\nLife Sciences Conference, taking place September 9-10, 2026, in New York City.\nDr. Phillip Chan, CEO and Peter Mariani, CFO will be attending the conference,\ndelivering an investor presentation and participating in scheduled 1-on-1\nmeetings with investors.\n\nInvestor Presentation:\nDate: Thursday, September 10, 2026\nTime: 2:50pm EST\nLocation: The Westin New York Grand Central, 212 E 42nd St, New York, NY\nMore info: https://moodycapital.com/conference/\n\nAbout the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences\nConference\nThe Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference\nbrings together public and private growth companies, pioneering innovators,\ninvestors, C-suite executives and industry professionals across biotechnology,\nmedical devices, pharmaceuticals, healthcare technology and other growth\nindustries. The two-day conference features company presentations, one-on-one\ninvestor meetings, fireside chats, capital markets and financing panels, and\nnetworking opportunities with institutional investors and family offices.\n\nAbout CytoSorbents Corporation (NASDAQ: CTSO)\nCytoSorbents Corporation (https://api.newsfilecorp.com/redirect/1KbA2iwqkB) is\na leader in the treatment of life-threatening conditions in the intensive care\nunit and cardiac surgery through blood purification. CytoSorbents' proprietary\nblood purification technologies are based on biocompatible, highly porous\npolymer beads that can actively remove toxic substances from blood and other\nbodily fluids by pore capture and surface adsorption. Cartridges filled with\nthese beads can be used with standard blood pumps already in the hospital\n(e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal\nmembrane oxygenation or ECMO, and heart-lung machines), where blood is\nrepeatedly recirculated outside the body, through our cartridges where toxic\nsubstances are removed, and then back into the body. CytoSorbents'\ntechnologies are used in a number of broad applications. Specifically, two\nimportant applications are 1) the removal of blood thinners during and after\ncardiothoracic surgery to reduce the risk of severe bleeding, and 2) the\nremoval of inflammatory agents and toxins in common critical illnesses that\ncan lead to massive inflammation, organ failure and patient death. The breadth\nof these critical illnesses includes, for example, sepsis, burn injury,\ntrauma, lung injury, liver failure, cytokine storm and cytokine release\nsyndrome, and pancreatitis as well as the removal of liver toxins that\naccumulate in acute liver dysfunction or failure, and the removal of myoglobin\nin severe rhabdomyolysis that can otherwise lead to renal failure. In these\ndiseases, the risk of death can be extremely high, and there are few, if any,\neffective treatments.\n\nCytoSorbents' lead product, CytoSorb®\n(https://api.newsfilecorp.com/redirect/A8kJRU4nE1), is approved in the\nEuropean Union and distributed in over 70 countries worldwide, with more than\n300,000 devices used cumulatively to date. CytoSorb® was originally launched\nin the European Union under CE mark as the first cytokine adsorber. Additional\nCE mark extensions were granted for bilirubin and myoglobin removal in\nclinical conditions such as liver disease and trauma, respectively, and for\nticagrelor (https://api.newsfilecorp.com/redirect/ZEy30fbQKL) and rivaroxaban\n(https://api.newsfilecorp.com/redirect/any5btXr5w) removal in cardiothoracic\nsurgery procedures. CytoSorb® has also received FDA Emergency Use\nAuthorization (https://api.newsfilecorp.com/redirect/24bA2fWbYz) in the United\nStates for use in adult critically ill COVID-19 patients with impending or\nconfirmed respiratory failure. CytoSorb® is not yet approved or cleared in\nthe United States.\n\nIn the U.S. and Canada, CytoSorbents is developing the DrugSorb®-ATR\nantithrombotic removal system, an investigational device based on an\nequivalent polymer technology to CytoSorb®, to reduce the severity of\nperioperative bleeding in high-risk surgery due to blood thinning drugs. It\nhas received two FDA Breakthrough Device Designations\n(https://api.newsfilecorp.com/redirect/Mq3gktg8L3): one for the removal of\nticagrelor (https://api.newsfilecorp.com/redirect/bgyL7i0Xp1) and another for\nthe removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban\n(https://api.newsfilecorp.com/redirect/JkpOAsYEqX) in a cardiopulmonary bypass\ncircuit during urgent cardiothoracic surgery. The Company is actively pursuing\nregulatory approval of DrugSorb®-ATR with the U.S. FDA and will pursue\nregulatory approval with Health Canada with better visibility from the FDA.\nDrugSorb®-ATR is not yet granted or approved in either the U.S. or Canada.\n\nThe Company has numerous marketed products and products under development\nbased upon this unique blood purification technology protected by many issued\nU.S. and international patents and registered trademarks, and multiple patent\napplications pending, including ECOS-300CY®, CytoSorb-XL™,\nHemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb®,\nContrastSorb, PuriFi®, HotSwap™ and others. For more information, please\nvisit the Company's website at https://ir.cytosorbents.com/ and follow us on\nFacebook (https://api.newsfilecorp.com/redirect/XEy48fWm2p) and X\n(https://api.newsfilecorp.com/redirect/DOLmAtYRK5) and LinkedIn\n(https://api.newsfilecorp.com/redirect/rpa4RUao1G).\n\nForward-Looking Statements\nThis press release includes forward-looking statements intended to qualify for\nthe safe harbor from liability established by the Private Securities\nLitigation Reform Act of 1995. These forward-looking statements include, but\nare not limited to, statements about our plans, objectives, future targets and\noutlooks for our business, representations and contentions, and the outcome of\nour regulatory submissions, and are not historical facts and typically are\nidentified by use of terms such as \"may,\" \"should,\" \"could,\" \"expect,\" \"plan,\"\n\"anticipate,\" \"believe,\" \"estimate,\" \"predict,\" \"potential,\" \"continue\" and\nsimilar words, although some forward-looking statements are expressed\ndifferently. You should be aware that the forward-looking statements in this\npress release represent management's current judgment and expectations, but\nour actual results, events and performance could differ materially from those\nin the forward-looking statements. Factors which could cause or contribute to\nsuch differences include, but are not limited to, our restructuring of our\ndirect sales team and strategy in Germany, ability to successfully obtain U.S.\nFDA and Health Canada marketing authorization or approval, our ability to\nreduce costs, optimize operations, and achieve cash-flow break-even in the\nsecond half of 2026, our ability to appropriately finance the Company, and the\nrisks discussed in our Annual Report on Form 10-K, filed with the SEC on March\n30, 2026, as updated by the risks reported in our Quarterly Reports on Form\n10-Q, and in the press releases and other communications to shareholders\nissued by us from time to time which attempt to advise interested parties of\nthe risks and factors which may affect our business. We caution you not to\nplace undue reliance upon any such forward-looking statements. We undertake no\nobligation to publicly update or revise any forward-looking statements,\nwhether as a result of new information, future events, or otherwise, other\nthan as required under the Federal securities laws.\n\nPlease Click to Follow Us on Facebook\n(https://api.newsfilecorp.com/redirect/VvyVpfWBrJ) and X\n(https://api.newsfilecorp.com/redirect/zAaBLsKGNr) and LinkedIn\n(https://api.newsfilecorp.com/redirect/Lq0wAtpAW1)\n\nCompany Contact:\nPeter J. Mariani, Chief Financial Officer\npmariani@cytosorbents.com\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/312850","article_body_html":"","raw_payload":{"data":{"id":"nNFC8YcSLt-20260904","title":"CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference","author":"Newsfile Corp","ticker":"CTSO","created":"2026-09-04T13:09:35.616Z","tickers":["CTSO"],"exchange":"NASDAQ","article_body":"Princeton, New Jersey--(Newsfile Corp. - September 4, 2026) - CytoSorbents\nCorporation (https://api.newsfilecorp.com/redirect/87VN2t5nvJ) (NASDAQ: CTSO),\na leader in the treatment of life-threatening conditions in the intensive care\nunit and cardiac surgery using blood purification, is pleased to announce its\nparticipation at the upcoming Moody Capital Solutions 2026 Disruptive Growth &\nLife Sciences Conference, taking place September 9-10, 2026, in New York City.\nDr. Phillip Chan, CEO and Peter Mariani, CFO will be attending the conference,\ndelivering an investor presentation and participating in scheduled 1-on-1\nmeetings with investors.\n\nInvestor Presentation:\nDate: Thursday, September 10, 2026\nTime: 2:50pm EST\nLocation: The Westin New York Grand Central, 212 E 42nd St, New York, NY\nMore info: https://moodycapital.com/conference/\n\nAbout the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences\nConference\nThe Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference\nbrings together public and private growth companies, pioneering innovators,\ninvestors, C-suite executives and industry professionals across biotechnology,\nmedical devices, pharmaceuticals, healthcare technology and other growth\nindustries. The two-day conference features company presentations, one-on-one\ninvestor meetings, fireside chats, capital markets and financing panels, and\nnetworking opportunities with institutional investors and family offices.\n\nAbout CytoSorbents Corporation (NASDAQ: CTSO)\nCytoSorbents Corporation (https://api.newsfilecorp.com/redirect/1KbA2iwqkB) is\na leader in the treatment of life-threatening conditions in the intensive care\nunit and cardiac surgery through blood purification. CytoSorbents' proprietary\nblood purification technologies are based on biocompatible, highly porous\npolymer beads that can actively remove toxic substances from blood and other\nbodily fluids by pore capture and surface adsorption. Cartridges filled with\nthese beads can be used with standard blood pumps already in the hospital\n(e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal\nmembrane oxygenation or ECMO, and heart-lung machines), where blood is\nrepeatedly recirculated outside the body, through our cartridges where toxic\nsubstances are removed, and then back into the body. CytoSorbents'\ntechnologies are used in a number of broad applications. Specifically, two\nimportant applications are 1) the removal of blood thinners during and after\ncardiothoracic surgery to reduce the risk of severe bleeding, and 2) the\nremoval of inflammatory agents and toxins in common critical illnesses that\ncan lead to massive inflammation, organ failure and patient death. The breadth\nof these critical illnesses includes, for example, sepsis, burn injury,\ntrauma, lung injury, liver failure, cytokine storm and cytokine release\nsyndrome, and pancreatitis as well as the removal of liver toxins that\naccumulate in acute liver dysfunction or failure, and the removal of myoglobin\nin severe rhabdomyolysis that can otherwise lead to renal failure. In these\ndiseases, the risk of death can be extremely high, and there are few, if any,\neffective treatments.\n\nCytoSorbents' lead product, CytoSorb®\n(https://api.newsfilecorp.com/redirect/A8kJRU4nE1), is approved in the\nEuropean Union and distributed in over 70 countries worldwide, with more than\n300,000 devices used cumulatively to date. CytoSorb® was originally launched\nin the European Union under CE mark as the first cytokine adsorber. Additional\nCE mark extensions were granted for bilirubin and myoglobin removal in\nclinical conditions such as liver disease and trauma, respectively, and for\nticagrelor (https://api.newsfilecorp.com/redirect/ZEy30fbQKL) and rivaroxaban\n(https://api.newsfilecorp.com/redirect/any5btXr5w) removal in cardiothoracic\nsurgery procedures. CytoSorb® has also received FDA Emergency Use\nAuthorization (https://api.newsfilecorp.com/redirect/24bA2fWbYz) in the United\nStates for use in adult critically ill COVID-19 patients with impending or\nconfirmed respiratory failure. CytoSorb® is not yet approved or cleared in\nthe United States.\n\nIn the U.S. and Canada, CytoSorbents is developing the DrugSorb®-ATR\nantithrombotic removal system, an investigational device based on an\nequivalent polymer technology to CytoSorb®, to reduce the severity of\nperioperative bleeding in high-risk surgery due to blood thinning drugs. It\nhas received two FDA Breakthrough Device Designations\n(https://api.newsfilecorp.com/redirect/Mq3gktg8L3): one for the removal of\nticagrelor (https://api.newsfilecorp.com/redirect/bgyL7i0Xp1) and another for\nthe removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban\n(https://api.newsfilecorp.com/redirect/JkpOAsYEqX) in a cardiopulmonary bypass\ncircuit during urgent cardiothoracic surgery. The Company is actively pursuing\nregulatory approval of DrugSorb®-ATR with the U.S. FDA and will pursue\nregulatory approval with Health Canada with better visibility from the FDA.\nDrugSorb®-ATR is not yet granted or approved in either the U.S. or Canada.\n\nThe Company has numerous marketed products and products under development\nbased upon this unique blood purification technology protected by many issued\nU.S. and international patents and registered trademarks, and multiple patent\napplications pending, including ECOS-300CY®, CytoSorb-XL™,\nHemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb®,\nContrastSorb, PuriFi®, HotSwap™ and others. For more information, please\nvisit the Company's website at https://ir.cytosorbents.com/ and follow us on\nFacebook (https://api.newsfilecorp.com/redirect/XEy48fWm2p) and X\n(https://api.newsfilecorp.com/redirect/DOLmAtYRK5) and LinkedIn\n(https://api.newsfilecorp.com/redirect/rpa4RUao1G).\n\nForward-Looking Statements\nThis press release includes forward-looking statements intended to qualify for\nthe safe harbor from liability established by the Private Securities\nLitigation Reform Act of 1995. These forward-looking statements include, but\nare not limited to, statements about our plans, objectives, future targets and\noutlooks for our business, representations and contentions, and the outcome of\nour regulatory submissions, and are not historical facts and typically are\nidentified by use of terms such as \"may,\" \"should,\" \"could,\" \"expect,\" \"plan,\"\n\"anticipate,\" \"believe,\" \"estimate,\" \"predict,\" \"potential,\" \"continue\" and\nsimilar words, although some forward-looking statements are expressed\ndifferently. You should be aware that the forward-looking statements in this\npress release represent management's current judgment and expectations, but\nour actual results, events and performance could differ materially from those\nin the forward-looking statements. Factors which could cause or contribute to\nsuch differences include, but are not limited to, our restructuring of our\ndirect sales team and strategy in Germany, ability to successfully obtain U.S.\nFDA and Health Canada marketing authorization or approval, our ability to\nreduce costs, optimize operations, and achieve cash-flow break-even in the\nsecond half of 2026, our ability to appropriately finance the Company, and the\nrisks discussed in our Annual Report on Form 10-K, filed with the SEC on March\n30, 2026, as updated by the risks reported in our Quarterly Reports on Form\n10-Q, and in the press releases and other communications to shareholders\nissued by us from time to time which attempt to advise interested parties of\nthe risks and factors which may affect our business. We caution you not to\nplace undue reliance upon any such forward-looking statements. We undertake no\nobligation to publicly update or revise any forward-looking statements,\nwhether as a result of new information, future events, or otherwise, other\nthan as required under the Federal securities laws.\n\nPlease Click to Follow Us on Facebook\n(https://api.newsfilecorp.com/redirect/VvyVpfWBrJ) and X\n(https://api.newsfilecorp.com/redirect/zAaBLsKGNr) and LinkedIn\n(https://api.newsfilecorp.com/redirect/Lq0wAtpAW1)\n\nCompany Contact:\nPeter J. Mariani, Chief Financial Officer\npmariani@cytosorbents.com\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/312850"},"type":"article","timestamp":"2026-09-04T13:09:35.659689222Z","server_sent_at_ms":1788527375659},"received_at":"2026-09-04T13:09:35.720Z","source_url":"https://www.newsfilecorp.com/release/312850"},"analysis":{"id":"125052","press_release_id":"136174","analysis_json":{"industry":{"label":"Health Care Equipment","sector":"Health Care"},"redFlags":["Forward-looking statements flag outstanding financing needs and an unmet cash-flow break-even target for H2 2026","DrugSorb-ATR remains unapproved in the U.S. and Canada; regulatory path depends on pending FDA decision"],"eventType":"other","narrative":"CytoSorbents (NASDAQ: CTSO) announced its participation in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026 in New York City.\n\nCEO Dr. Phillip Chan and CFO Peter Mariani will attend, delivering an investor presentation on September 10 at 2:50pm EST and holding scheduled 1-on-1 meetings with institutional investors and family offices.\n\nThe release contains no new financial, clinical, or regulatory disclosures; forward-looking-statement language reiterates existing risks including financing needs, restructuring of the German direct sales team, and a targeted cash-flow break-even in the second half of 2026.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine investor-conference appearance for CTSO with no new data — log for event calendar, suppress posting."},"keyFigures":{"customDimensions":{"cytosorb_devices_used_cumulative":300000,"countries_with_cytosorb_distribution":"70+"}},"namedEntities":{"people":[{"name":"Dr. Phillip Chan","role":"CEO"},{"name":"Peter Mariani","role":"CFO"}],"products":["CytoSorb®","DrugSorb®-ATR"],"companies":[{"name":"CytoSorbents Corporation","ticker":"CTSO","relationship":"filer/issuer"},{"name":"Moody Capital Solutions","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor-relations announcement of conference participation with no new financial, clinical, or regulatory information. The company overview is recycled boilerplate."},"tickerRelevance":{"others":[],"primary":"CTSO"},"globalImportance":6,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"routine-investor-conference","issuerAuthored":true,"newInformation":false,"householdBrandBoost":false,"retailFavoriteBoost":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"CytoSorbents (NASDAQ: CTSO) announced its participation in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026 in New York City.\n\nCEO Dr. Phillip Chan and CFO Peter Mariani will attend, delivering an investor presentation on September 10 at 2:50pm EST and holding scheduled 1-on-1 meetings with institutional investors and family offices.\n\nThe release contains no new financial, clinical, or regulatory disclosures; forward-looking-statement language reiterates existing risks including financing needs, restructuring of the German direct sales team, and a targeted cash-flow break-even in the second half of 2026.","key_figures":{"customDimensions":{"cytosorb_devices_used_cumulative":300000,"countries_with_cytosorb_distribution":"70+"}},"named_entities":{"people":[{"name":"Dr. Phillip Chan","role":"CEO"},{"name":"Peter Mariani","role":"CFO"}],"products":["CytoSorb®","DrugSorb®-ATR"],"companies":[{"name":"CytoSorbents Corporation","ticker":"CTSO","relationship":"filer/issuer"},{"name":"Moody Capital Solutions","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-04T13:10:53.787Z","global_importance":6,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"routine-investor-conference","issuerAuthored":true,"newInformation":false,"householdBrandBoost":false,"retailFavoriteBoost":false}},"durationMs":78057,"modelName":"glm-4.7"}}